Annual FCF
-$508.61 M
+$29.43 M+5.47%
December 31, 2023
Summary
- As of February 12, 2025, ASND annual free cash flow is -$508.61 million, with the most recent change of +$29.43 million (+5.47%) on December 31, 2023.
- During the last 3 years, ASND annual FCF has fallen by -$173.88 million (-51.95%).
- ASND annual FCF is now -7587.09% below its all-time high of $6.79 million, reached on December 31, 2013.
Performance
ASND Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
N/A
September 30, 2024
Summary
- ASND quarterly free cash flow is not available.
Performance
ASND Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM FCF
N/A
September 30, 2024
Summary
- ASND TTM free cash flow is not available.
Performance
ASND TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
ASND Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +5.5% | - | - |
| 3 y3 years | -52.0% | - | - |
| 5 y5 years | -204.5% | - | - |
ASND Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +5.5% | ||||
| 5 y | 5-year | -150.9% | +5.5% | ||||
| alltime | all time | -7587.1% | +5.5% |
Ascendis Pharma A/S Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2024 | - | -$110.55 M(+155.5%) | -$460.07 M(-9.5%) |
| Dec 2023 | -$508.61 M(-5.5%) | -$43.27 M(-68.3%) | -$508.61 M(-20.0%) |
| Sep 2023 | - | -$136.36 M(-19.7%) | -$635.97 M(+8.3%) |
| Jun 2023 | - | -$169.89 M(+6.8%) | -$587.18 M(+7.5%) |
| Mar 2023 | - | -$159.10 M(-6.8%) | -$546.09 M(+1.5%) |
| Dec 2022 | -$538.04 M(+2.9%) | -$170.63 M(+94.9%) | -$538.04 M(+3.4%) |
| Sep 2022 | - | -$87.56 M(-32.0%) | -$520.28 M(-6.4%) |
| Jun 2022 | - | -$128.80 M(-14.7%) | -$555.66 M(-2.5%) |
| Mar 2022 | - | -$151.04 M(-1.2%) | -$570.03 M(+9.0%) |
| Dec 2021 | -$522.83 M(+56.2%) | -$152.87 M(+24.3%) | -$522.83 M(+10.4%) |
| Sep 2021 | - | -$122.95 M(-14.1%) | -$473.68 M(+9.2%) |
| Jun 2021 | - | -$143.17 M(+37.9%) | -$433.68 M(+21.1%) |
| Mar 2021 | - | -$103.84 M(+0.1%) | -$358.09 M(+7.0%) |
| Dec 2020 | -$334.73 M(+65.1%) | -$103.72 M(+25.0%) | -$334.73 M(+16.1%) |
| Sep 2020 | - | -$82.96 M(+22.8%) | -$288.38 M(+5.8%) |
| Jun 2020 | - | -$67.58 M(-16.0%) | -$272.67 M(+29.1%) |
| Mar 2020 | - | -$80.48 M(+40.3%) | -$211.27 M(+4.2%) |
| Dec 2019 | -$202.74 M(+21.4%) | -$57.37 M(-14.7%) | -$202.74 M(+6.4%) |
| Sep 2019 | - | -$67.25 M(+988.7%) | -$190.50 M(+7.8%) |
| Jun 2019 | - | -$6.18 M(-91.4%) | -$176.74 M(-8.8%) |
| Mar 2019 | - | -$71.94 M(+59.4%) | -$193.70 M(+16.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$167.03 M(+53.6%) | -$45.14 M(-15.6%) | -$167.03 M(+14.1%) |
| Sep 2018 | - | -$53.49 M(+131.1%) | -$146.42 M(+15.4%) |
| Jun 2018 | - | -$23.14 M(-48.9%) | -$126.83 M(-3.2%) |
| Mar 2018 | - | -$45.26 M(+84.5%) | -$130.99 M(+20.4%) |
| Dec 2017 | -$108.77 M(+61.5%) | -$24.53 M(-27.6%) | -$108.77 M(+6.2%) |
| Sep 2017 | - | -$33.89 M(+24.1%) | -$102.37 M(+19.1%) |
| Jun 2017 | - | -$27.30 M(+18.5%) | -$85.97 M(+16.5%) |
| Mar 2017 | - | -$23.04 M(+27.0%) | -$73.81 M(+9.6%) |
| Dec 2016 | -$67.35 M(+36.4%) | -$18.14 M(+3.7%) | -$67.35 M(+11.1%) |
| Sep 2016 | - | -$17.49 M(+15.4%) | -$60.64 M(+6.0%) |
| Jun 2016 | - | -$15.15 M(-8.6%) | -$57.19 M(-1.1%) |
| Mar 2016 | - | -$16.57 M(+45.0%) | -$57.81 M(+17.1%) |
| Dec 2015 | -$49.39 M(+97.5%) | -$11.43 M(-18.6%) | -$49.39 M(+2.4%) |
| Sep 2015 | - | -$14.04 M(-11.0%) | -$48.24 M(+25.6%) |
| Jun 2015 | - | -$15.77 M(+93.6%) | -$38.41 M(+30.1%) |
| Mar 2015 | - | -$8.15 M(-20.7%) | -$29.52 M(+18.0%) |
| Dec 2014 | -$25.01 M(-468.2%) | -$10.28 M(+144.1%) | -$25.01 M(+69.8%) |
| Sep 2014 | - | -$4.21 M(-38.8%) | -$14.73 M(+40.0%) |
| Jun 2014 | - | -$6.88 M(+89.2%) | -$10.52 M(+189.2%) |
| Mar 2014 | - | -$3.64 M | -$3.64 M |
| Dec 2013 | $6.79 M(-660.3%) | - | - |
| Dec 2012 | -$1.21 M | - | - |
FAQ
- What is Ascendis Pharma A/S annual free cash flow?
- What is the all time high annual FCF for Ascendis Pharma A/S?
- What is Ascendis Pharma A/S annual FCF year-on-year change?
- What is the all time high quarterly FCF for Ascendis Pharma A/S?
- What is the all time high TTM FCF for Ascendis Pharma A/S?
What is Ascendis Pharma A/S annual free cash flow?
The current annual FCF of ASND is -$508.61 M
What is the all time high annual FCF for Ascendis Pharma A/S?
Ascendis Pharma A/S all-time high annual free cash flow is $6.79 M
What is Ascendis Pharma A/S annual FCF year-on-year change?
Over the past year, ASND annual free cash flow has changed by +$29.43 M (+5.47%)
What is the all time high quarterly FCF for Ascendis Pharma A/S?
Ascendis Pharma A/S all-time high quarterly free cash flow is -$3.64 M
What is the all time high TTM FCF for Ascendis Pharma A/S?
Ascendis Pharma A/S all-time high TTM free cash flow is -$3.64 M